🔍

Vivo Bio Tech Ltd (511509)

📊 BSE: 511509 🏢 Biotechnology 📢 Latest filing: 13 Oct 2026

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Vivo Bio's revenue was ₹14.3 Cr (+14.1% year on year, +0.6% on the previous quarter), and net profit ₹0.2 Cr (-86.0% year on year); the operating margin was 35.4%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹14.3	+14.1%	+0.6%
Operating profit	₹5.1	-7.8%	+13.5%
Net profit	₹0.2	-86.0%	from loss
EPS (₹)	0.08	-88.1%	from loss
Operating margin	35.4%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Vivo Bio Tech Reports Fire Accident at Telangana Research Facility; Damage Under Assessment

🔴 NEGATIVE ⭐ 7/10

OTHER 📅 13 Oct 2026, 03:33 PM

Vivo Bio Tech Ltd reported a fire incident in the early hours of October 13, 2026, at its research facility located in Gajwel, Siddipet District, Telangana. The fire caused extensive damage to laboratory rooms, scientific equipment, plant and machinery, as well as sponsor test items, pathology specimens, and the PICO facility. No injuries or casualties were reported, and the company stated that assets are adequately insured, with insurance claim processes underway. With TTM revenue standing at Rs 55 Cr and TTM PAT at -Rs 3 Cr, any operational disruption from sample destruction and lab downtime could pressure upcoming quarters.

Fire broke out in early hours of October 13, 2026, at research facility in Survey No. 349/A, Gajwel, Telangana
Damage reported to laboratory rooms, scientific equipment, plant & machinery, Pathology Laboratory, and PICO facility
Valuable sponsor test items, samples for ongoing and future studies, and pathology specimens were destroyed
Zero casualties or injuries reported; assets are stated to be adequately covered by insurance
Expected quantum of financial loss and operational disruption are currently under assessment

💡 Track subsequent exchange filings for the quantified loss, insurance settlement timelines, and any operational downtime impact on quarterly revenue and sponsor contracts.

Vivo Bio Tech Reports Nil Physical Share Transfer Re-Lodgement Requests for September 2026

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 10 Oct 2026, 05:34 PM

Vivo Bio Tech Limited submitted its monthly compliance report regarding the re-lodgement of transfer requests for physical shares for the period ended September 2026. As per the report from Registrar and Share Transfer Agent Aarthi Consultants Private Limited, zero requests were received, approved, or rejected during the month. The filing is a standard compliance report required under SEBI Circular dated January 30, 2026, and presents zero operational or financial impact.

Number of requests received during the month ended September 2026 was NIL
Number of requests approved and processed was NIL
Number of requests rejected during the month was NIL
Report submitted pursuant to SEBI Circular No. SEBI/HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026

💡 No action is required as this is a recurring regulatory disclosure. Track upcoming quarterly earnings for updates on core operations.

6.27 Lakh Convertible Equity Warrants at Rs 45 Expire Unexercised by Allottee

🟡 NEUTRAL ⭐ 3/10

FUNDRAISE 📅 24 Aug 2026, 07:23 PM

Vivo Bio Tech Ltd announced that 6,27,409 convertible equity warrants, out of an original issue of 25,00,000 warrants allotted on February 24, 2025, have expired without exercise. The warrants had an issue price of Rs 45 (Face value Rs 10 + Premium Rs 35) and were allotted to Dwight Technologies Private Limited. The lapse occurred upon completion of the mandatory 18-month tenure on August 24, 2026, pursuant to SEBI ICDR Regulations. With current market prices around Rs 19.30, the warrants were significantly out-of-the-money.

6,27,409 warrants expired unexercised out of 25,00,000 total warrants issued
Warrant issue price was Rs 45 per share (FV Rs 10 + Premium Rs 35)
Allotment date was February 24, 2025; 18-month tenure completed on August 24, 2026
Allottee involved was Dwight Technologies Private Limited

💡 Track subsequent disclosures for confirmation of warrant subscription money forfeiture to the capital reserve.

Vivo Bio Tech Approves Re-Appointment of Two Whole-Time Directors for 5-Year Terms

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 22 Aug 2026, 07:43 PM

Vivo Bio Tech Ltd's Board of Directors has approved the re-appointment of two Whole-Time Directors for 5-year terms, subject to shareholder approval at the upcoming AGM on September 30, 2026. Mr. Sri Kalyan Kompella has been re-appointed for 5 years from November 03, 2026, to November 02, 2031. Dr. Sankaranarayanan Alangudi has been re-appointed for 5 years from January 06, 2027, to January 05, 2032. Additionally, Whole-Time Director Mr. Kalyan Ram Mangipudi's reappointment upon retirement by rotation was approved.

39th AGM scheduled for Wednesday, September 30, 2026, via Video Conferencing
Re-appointment of Sri Kalyan Kompella as Whole-Time Director for a 5-year term (Nov 3, 2026 to Nov 2, 2031)
Re-appointment of Dr. Sankaranarayanan Alangudi as Whole-Time Director for a 5-year term (Jan 6, 2027 to Jan 5, 2032)
Approval of Whole-Time Director Kalyan Ram Mangipudi retiring by rotation and seeking reappointment

💡 Track voting outcomes for these board re-appointments at the 39th AGM on September 30, 2026, alongside upcoming Q2 FY27 earnings performance.

Vivo Bio Tech Schedules 39th AGM on Sept 30, 2026; Approves Whole-Time Director Re-Appointments

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 22 Aug 2026, 07:40 PM

Vivo Bio Tech Limited announced the outcome of its Board Meeting held on August 22, 2026. The company scheduled its 39th Annual General Meeting (AGM) for Wednesday, September 30, 2026, via Video Conferencing. The Board approved the 5-year re-appointments of Whole-time Directors Mr. Sri Kalyan Kompella (effective Nov 3, 2026 to Nov 2, 2031) and Dr. Sankaranarayanan Alangudi (effective Jan 6, 2027 to Jan 5, 2032), alongside the rotational re-appointment of Mr. Kalyan Ram Mangipudi, subject to shareholder approval.

39th AGM scheduled to be held on September 30, 2026, through Video Conferencing
Re-appointment of Mr. Sri Kalyan Kompella as Whole-Time Director for a 5-year term from November 3, 2026, to November 2, 2031
Re-appointment of Dr. Sankaranarayanan Alangudi as Whole-Time Director for a 5-year term from January 6, 2027, to January 5, 2032
Re-appointment of Mr. Kalyan Ram Mangipudi as Whole-Time Director, retiring by rotation

💡 Track shareholder voting outcomes at the 39th AGM on September 30, 2026, and look for upcoming annual report disclosures regarding strategic initiatives.

8.1 Lakh Promoter Warrants Issued at Rs 45 Expire Unexercised at Vivo Bio Tech

🟡 NEUTRAL ⭐ 4/10

FUNDRAISE 📅 21 Aug 2026, 07:04 PM

Vivo Bio Tech Limited disclosed that 8,10,000 convertible equity warrants out of 12,00,000 total warrants allotted to promoters have expired unexercised. The warrants were allotted on February 21, 2025, at an issue price of Rs 45 per warrant (Face Value Rs 10 + Premium Rs 35). The statutory 18-month conversion period lapsed on August 21, 2026, leaving 3,50,000 warrants expired for Kompella Lopa Mudra and 4,60,000 warrants for Kompella Modini, as the market price (Rs 19.3) remained significantly below the warrant strike price.

8,10,000 warrants expired unexercised out of 12,00,000 warrants originally allotted.
Warrants were issued at Rs 45 each (Face Value Rs 10 + Premium Rs 35) on February 21, 2025.
Promoter Kompella Lopa Mudra let 3,50,000 warrants lapse out of 6,00,000 allotted.
Promoter Kompella Modini let 4,60,000 warrants lapse out of 6,00,000 allotted.
Warrant validity completed its 18-month tenure on August 21, 2026.

💡 Track the upcoming quarterly shareholding patterns and balance sheet disclosures to verify forfeiture of the upfront warrant subscription amounts.

Vivo Bio Tech reports expiry of 483 convertible warrants issued at Rs 45 each

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 20 Aug 2026, 06:51 PM

Vivo Bio Tech Limited has informed the exchanges that 483 convertible equity warrants, out of an original issue of 26,00,000 warrants, have expired unexercised upon completion of their 18-month tenure on August 20, 2026. The warrants were originally allotted to Antique Infotech Private Limited on February 20, 2025, at an issue price of Rs 45 per warrant. Given that only 483 warrants (worth approximately Rs 21,735) lapsed, the financial impact on the company is immaterial.

483 convertible equity warrants expired unexercised out of 26,00,000 issued warrants
Warrants were issued at Rs 45 each (Face Value Rs 10 and Premium Rs 35)
Allotment date was February 20, 2025, reaching completion of 18-month tenure on August 20, 2026
Allottee was Antique Infotech Private Limited

💡 Track subsequent shareholding patterns to verify final diluted share capital following the expiry of the warrant tenure.

Vivo Bio Tech Q1 Revenue up 14% YoY to ₹14.28 Cr; Net Profit drops 86% to ₹0.19 Cr

🔴 NEGATIVE ⭐ 6/10

EARNINGS 📅 13 Jul 2026, 07:49 PM

Vivo Bio Tech reported a 14.1% YoY increase in consolidated revenue to ₹1,427.97 Lacs for the quarter ended June 30, 2026. However, net profit plummeted by 86% YoY to ₹18.76 Lacs, down from ₹133.71 Lacs in the previous year's corresponding quarter. This sharp decline is primarily attributed to a 47.7% surge in employee costs and a 33.6% increase in depreciation expenses. Consequently, the net profit margin has compressed significantly to approximately 1.3%.

Consolidated Revenue from operations increased 14.1% YoY to ₹1,427.97 Lacs.
Net Profit after tax fell 86% YoY to ₹18.76 Lacs from ₹133.71 Lacs.
Employee costs rose significantly by 47.7% YoY to ₹472.98 Lacs.
Depreciation and amortization expenses increased 33.6% YoY to ₹353.17 Lacs.
Basic and Diluted EPS dropped to ₹0.08 from ₹0.74 in the year-ago quarter.

💡 Investors should monitor whether the sharp rise in employee and depreciation costs is tied to new capacity that will scale revenue in coming quarters, or if it represents a permanent structural decline in margins.

Vivo Bio Tech Q1 PAT Drops 86% YoY to ₹18.76 Lacs Despite 14% Revenue Growth

🔴 NEGATIVE ⭐ 6/10

EARNINGS 📅 13 Jul 2026, 07:41 PM

Vivo Bio Tech reported a consolidated revenue of ₹1,427.97 Lacs for Q1 FY27, representing a 14.1% increase from ₹1,251.16 Lacs in the year-ago period. However, Net Profit plummeted by 86% YoY to ₹18.76 Lacs, down from ₹133.71 Lacs, as operating expenses surged. The profit decline was driven by a 47.7% rise in employee costs and a 33.6% increase in depreciation, significantly compressing margins. Consequently, the Basic EPS fell sharply to ₹0.08 from ₹0.74 YoY.

Consolidated Revenue from operations grew 14.1% YoY to ₹1,427.97 Lacs
Net Profit After Tax (PAT) declined 86% YoY to ₹18.76 Lacs
Employee costs increased significantly by 47.7% YoY to ₹472.98 Lacs
Depreciation and amortization expenses rose 33.6% YoY to ₹353.17 Lacs
Profit Before Tax (PBT) fell to ₹33.86 Lacs compared to ₹147.99 Lacs in Q1 FY26

💡 Investors should monitor the company's operating leverage and whether the increased employee and depreciation costs (likely from recent capacity additions) will be offset by higher revenue in subsequent quarters.

View All 511509 Announcements on Live Market Tracking →